Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 343

2.

Development of the semi-synthetic penicillins and cephalosporins.

Hamilton-Miller JM.

Int J Antimicrob Agents. 2008 Mar;31(3):189-92. doi: 10.1016/j.ijantimicag.2007.11.010. Epub 2008 Jan 8. Review.

PMID:
18248798
3.

Experiments I'll never forget: using NMR to watch beta-lactamase working, and using microtitre trays for minimum inhibitory concentration determination.

Hamilton-Miller JM.

Int J Antimicrob Agents. 2006 Sep;28(3):270-1. Epub 2006 Aug 7. No abstract available.

PMID:
16893629
4.

Antimicrobial properties of green tea catechins.

Taylor PW, Hamilton-Miller JM, Stapleton PD.

Food Sci Technol Bull. 2005;2:71-81.

5.

Correct use of the word 'fomites': its etymology is important.

Hamilton-Miller JM.

J Hosp Infect. 2005 Feb;59(2):165. No abstract available.

PMID:
15620455
6.

Anti-Staphylococcus aureus activity and oxacillin resistance modulating capacity of 3-O-acyl-catechins.

Stapleton PD, Shah S, Hamilton-Miller JM, Hara Y, Nagaoka Y, Kumagai A, Uesato S, Taylor PW.

Int J Antimicrob Agents. 2004 Oct;24(4):374-80.

PMID:
15380264
7.

Probiotics and prebiotics in the elderly.

Hamilton-Miller JM.

Postgrad Med J. 2004 Aug;80(946):447-51. Review.

8.

Antibiotic resistance from two perspectives: man and microbe.

Hamilton-Miller JM.

Int J Antimicrob Agents. 2004 Mar;23(3):209-12. Review.

PMID:
15164959
9.

Appreciation. Dr. Norman Heatley.

Hamilton-Miller JM.

J Antimicrob Chemother. 2004 May;53(5):691-2. No abstract available.

PMID:
15154415
10.

Modulation of beta-lactam resistance in Staphylococcus aureus by catechins and gallates.

Stapleton PD, Shah S, Anderson JC, Hara Y, Hamilton-Miller JM, Taylor PW.

Int J Antimicrob Agents. 2004 May;23(5):462-7.

PMID:
15120724
11.

Chemical and microbiologic aspects of penems, a distinct class of beta-lactams: focus on faropenem.

Hamilton-Miller JM.

Pharmacotherapy. 2003 Nov;23(11):1497-507. Review.

PMID:
14620395
12.

Some insights into the derivation and early uses of the word 'probiotic'.

Hamilton-Miller JM, Gibson GR, Bruck W.

Br J Nutr. 2003 Oct;90(4):845. No abstract available.

PMID:
14552330
13.

The role of probiotics in the treatment and prevention of Helicobacter pylori infection.

Hamilton-Miller JM.

Int J Antimicrob Agents. 2003 Oct;22(4):360-6. Review.

PMID:
14522098
14.

Distinguishing Pasteurella spp. from Haemophilus spp.: the problem revisited.

Hamilton-Miller JM.

Clin Microbiol Infect. 2003 Mar;9(3):243. No abstract available.

15.
16.
17.

Enzyme-catalyzed antimicrobial activation.

Hamilton-Miller JM.

Antimicrob Agents Chemother. 2002 Nov;46(11):3692; author reply 3692. No abstract available.

18.

Vancomycin-resistant Staphylococcus aureus: a real and present danger?

Hamilton-Miller JM.

Infection. 2002 Jun;30(3):118-24. Review.

PMID:
12120934
19.

'Think like a bacterium': a helpful concept to prolong the antibiotic era?

Hamilton-Miller JM.

Clin Microbiol Infect. 1998 Apr;4(4):177-178. No abstract available.

20.

Lactobacillus endocarditis caused by a probiotic organism.

Mackay AD, Taylor MB, Kibbler CC, Hamilton-Miller JM.

Clin Microbiol Infect. 1999 May;5(5):290-292. No abstract available.

21.

Deficiencies in microbiological quality and labelling of probiotic supplements.

Hamilton-Miller JM, Shah S.

Int J Food Microbiol. 2002 Jan 30;72(1-2):175-6. No abstract available.

PMID:
11852901
22.

Resistance to teicoplanin developing during treatment of methicillin-resistant Staphylococcus aureus infection.

Elsaghier AA, Aucken HM, Hamilton-Miller JM, Shaw S, Kibbler CC.

J Antimicrob Chemother. 2002 Feb;49(2):423-4. No abstract available.

PMID:
11815594
23.

Identity and antibiotic susceptibility of enterobacterial flora of salad vegetables.

Hamilton-Miller JM, Shah S.

Int J Antimicrob Agents. 2001 Jul;18(1):81-3.

PMID:
11463532
24.

Overview of cefixime use in community-acquired infections.

Hamilton-Miller JM.

Clin Microbiol Infect. 2000;6 Suppl 3:79-81. Review. No abstract available.

25.

Susceptibility of pneumococci to evernimicin: effect of CO2 and different methodologies.

Hamilton-Miller JM, Shah S, Loebenberg D.

Clin Microbiol Infect. 2001 Jun;7(6):339-40. No abstract available.

26.

Immunopharmacology of antibiotics: direct and indirect immunomodulation of defence mechanisms.

Hamilton-Miller JM.

J Chemother. 2001 Apr;13(2):107-11. Review.

PMID:
11330355
27.

Anti-cariogenic properties of tea (Camellia sinensis).

Hamilton-Miller JM.

J Med Microbiol. 2001 Apr;50(4):299-302. Review.

PMID:
11289514
28.
29.
30.

Activity of the tea component epicatechin gallate and analogues against methicillin-resistant Staphylococcus aureus.

Hamilton-Miller JM, Shah S.

J Antimicrob Chemother. 2000 Nov;46(5):852-3. No abstract available.

PMID:
11062217
31.

Sir Edward Abraham's contribution to the development of the cephalosporins: a reassessment.

Hamilton-Miller JM.

Int J Antimicrob Agents. 2000 Aug;15(3):179-84.

PMID:
10926439
32.

Efficacy studies of probiotics: a call for guidelines.

Hamilton-Miller JM, Gibson GR.

Br J Nutr. 1999 Jul;82(1):73-5. No abstract available.

PMID:
10655959
33.

Issues in urinary tract infections in the elderly.

Hamilton-Miller JM.

World J Urol. 1999 Dec;17(6):396-401. Review. No abstract available.

PMID:
10654370
34.

New BSAC sensitivity testing guidelines.

Hamilton-Miller JM.

J Antimicrob Chemother. 1999 Dec;44(6):850-1. No abstract available.

PMID:
10590292
35.

beta-lactams: variations on a chemical theme, with some surprising biological results.

Hamilton-Miller JM.

J Antimicrob Chemother. 1999 Dec;44(6):729-34. Review. No abstract available.

PMID:
10590272
36.

Glycopeptide-resistant staphylococci.

Hamilton-Miller JM.

Int J Antimicrob Agents. 1999 Sep;13(1):63-5. No abstract available.

PMID:
10563408
37.
38.
39.

Cefaclor into the millennium.

Brumfitt W, Hamilton-Miller JM.

J Chemother. 1999 Jun;11(3):163-78. Review.

PMID:
10435677
41.

Probiotics used in trials should be independently checked microbiologically.

Hamilton-Miller JM.

BMJ. 1999 Jul 17;319(7203):189-90. No abstract available.

42.
43.

Susceptibility testing of linezolid by two standard methods.

Hamilton-Miller JM, Shah S.

Eur J Clin Microbiol Infect Dis. 1999 Mar;18(3):225-7.

PMID:
10357061
44.

Comparative anti-anaerobic activity of Men 10700, a penem antibiotic.

Hamilton-Miller JM, Shah S.

Int J Antimicrob Agents. 1998 Nov;10(4):321-4.

PMID:
9916909
45.

In-vitro activity of a novel penem, Men 10700, against meningococci and gonococci, and the effect of a cysteine-containing supplement.

Hamilton-Miller JM, Shah S.

J Antimicrob Chemother. 1998 Oct;42(4):553-5. No abstract available.

PMID:
9818763
46.

A pilot study of Salix SST (saliva-stimulating lozenges) in post-irradiation xerostomia.

Senahayake F, Piggott K, Hamilton-Miller JM.

Curr Med Res Opin. 1998;14(3):155-9.

PMID:
9787981
47.

Efficacy and safety profile of long-term nitrofurantoin in urinary infections: 18 years' experience.

Brumfitt W, Hamilton-Miller JM.

J Antimicrob Chemother. 1998 Sep;42(3):363-71.

PMID:
9786476
48.
49.

Pasteurella multocida as an infectious cause of endocarditis.

Elsaghier AA, Kibbler CC, Hamilton-Miller JM.

Clin Infect Dis. 1998 Aug;27(2):410-1. No abstract available.

PMID:
9709904
50.

Supplemental Content

Loading ...
Support Center